O. Sabri et al., Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication, J CLIN END, 84(4), 1999, pp. 1229-1233
There is controversy whether simultaneous thyrostatic medication influences
the outcome of radioiodine (I-131) therapy in Graves' disease by reducing
the absorbed energy dose of I-131 when delivering a standard dose. We there
fore sought to ascertain whether the outcome of ablative I-131 therapy is i
n any way affected by simultaneous thyrostasis (carbimazole) by aiming for
a constant absorbed dose of 200-250 Gy. We prospectively studied 207 patien
ts with Graves' disease (106 with and 101 without simultaneous carbimazole
at the time of I-131 therapy). All patients were reexamined 3, 6, and 12 mo
nths after I-131 therapy. The 101 nonthyrostatic patients showed a highly s
ig nificantly greater success rate (93%) than the 106 thyrostatic patients
(49%). Stepwise logistic regression demonstrated that failure was related t
o the administration of carbimazole during I-131 therapy (P < 0.00005) and
the absorbed dose (P < 0.025), but was not related to free T-3, free T-4, T
SH receptor antibodies, or thyroid volume. The success rate was 100% in 93
nonthyrostatic patients with absorbed doses of 200 Gy or more, but was only
12.5% (1 of 8) for absorbed doses less than 200 Gy. Correlation between su
ccess and absorbed dose was significantly higher for nonthyrostatic than fo
r thyrostatic patients (r = 0.93 vs, r = 0.24). Sixteen patients who discon
tinued thyrostasis 1-3 days before I-131 therapy showed 94% successes.
Simultaneous thyrostasis is the decisive factor against a successful I-131
therapy even if the significantly reduced I-131 uptake/half-life values und
er thyrostasis are compensated with a higher delivered dose to ensure a com
parable absorbed dose, possibly due to the additionally effective radioprot
ective properties of carbimazole. Therefore, if clinically feasible, we rec
ommend discontinuing thyrostasis at least 1 day before beginning I-131 ther
apy, because even in hyperthyroid nonthyrostatic patients the success rate
was 100%.